Thyrocare Technologies Ltd (THYROCARE) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Thyrocare Technologies Ltd on NSE and BSE, with an AI summary of each filing.
Please find attached the Earnings Call Transcript held on October 29, 2026
Transcript · 02 Nov 2026, 6:24 pm
Please find attached Intimation regarding the Execution of Share Purchase Agreement
Others (Uncategorized) · 30 Oct 2026, 10:58 pm
Thyrocare Divests 100% Stake in Nueclear Healthcare for Rs. 141.40 Crore Thyrocare Technologies signed a Share Purchase Agreement on 30th Oct'26 to sell its 100% equity stake (1.11 crore shares) in wholly owned subsidiary Nueclear Healthcare Limited to Trovera Healthcare for ~Rs. 141.40 crore. Shareholders approved the transaction via special resolution on 29th Oct'26. The consideration comprises Rs. 81.90 crore in cash (subject to working capital adjustments) and Rs. 59.50 crore via 42,500 Compulsorily Convertible Preference Shares of Trovera at Rs. 14,000 each. The transaction is non-related party and subject to customary closing conditions.
Audio Recording of Earnings Conference Call for the Quarter and Half Year Ended September 30, 2026
Audio / Video · 30 Oct 2026, 2:34 am
Thyrocare Technologies Releases Q2 FY27 Post-Results Earnings Call Audio Recording Thyrocare Technologies Limited announced that the audio recording of its post-results earnings conference call, conducted on 29th Oct'26 at 06:00 PM IST, is available on the company's website. The call discussed the unaudited financial results for the quarter and half-year ended 30th Sep'26 with analysts and investors. The company stated that the written transcript of the earnings call will be shared shortly in compliance with SEBI listing regulations.
Please find attached the Investor Presentation on the unaudited financial results (standalone and consolidated) for the quarter and half year ended on September 30, 2026
Investor Presentation · 29 Oct 2026, 9:47 pm
Thyrocare Posts Strong Q2 FY27 Results and Divests Nueclear Healthcare Thyrocare reported Q2 FY27 consolidated revenue of INR 270.8 Cr (+25.1% YoY) and EBITDA of INR 89.3 Cr (+25.0% YoY) with a 33.0% margin. PAT before exceptions grew 25.7% YoY to INR 60.2 Cr, while reported PAT fell to INR 15.2 Cr due to a one-time INR 45.0 Cr goodwill impairment from divesting Nueclear Healthcare (NHL) for INR 141.4 Cr. Total active franchisees reached 12,911 (+27.1% YoY) and tests performed rose 27.4% YoY to 61.6 Mn. The company remains debt-free.
Please find attached the Press Release on the unaudited financial results (Standalone and Consolidated) for the quarter and half year ended on September 30, 2026
Press Release · 29 Oct 2026, 9:40 pm
Thyrocare Technologies Reports Robust Q2FY27 Results with 25.1% YoY Revenue Growth Thyrocare Technologies reported consolidated revenue of INR 270.8 Cr for Q2FY27, up 25.1% YoY, driven by a 26.7% YoY increase in Pathology. EBITDA grew 24.9% YoY to INR 89.3 Cr, while PAT before exceptional items rose 25.7% YoY to INR 60.2 Cr. Reported PAT stood at INR 15.2 Cr due to a one-time non-cash impairment of INR 45 Cr related to the proposed divestment of the NHL business. Test volumes rose 27.4% YoY to 61.6 million, supported by 12,911 active franchisees.
Please find enclosed the unaudited standalone and consolidated financial results of the Company for the quarter and half year ended on September 30, 2026
Financial Result · 29 Oct 2026, 9:29 pm
Please find enclosed outcome of the Board Meeting held on October 29, 2026, inter alia, approving the unaudited financial results for the quarter and half year ended September 30, 2026 ....
Outcome · 29 Oct 2026, 9:24 pm
Thyrocare Technologies Limited has submitted to the Exchange, outcome of board meeting held on October 29, 2026, inter-alia considered and approved the un-audited financial results for the quarter and half year ended September 30, 2026.
Outcome · 29 Oct 2026, 9:22 pm
Thyrocare Technologies Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crores) ■ Revenue: 271 (+25.1% YoY | +12.8% QoQ) ■ EBITDA: 89.3 (+25.1% YoY | +15.6% QoQ) ■ EBITDA Margin (%): 33.0 (+2 bps YoY | +78 bps QoQ) ■ PAT: 15.9 (-66.9% YoY | -69.6% QoQ) ■ EPS (INR): 0.95 (-68.3% YoY | -70.4% QoQ) Thyrocare Technologies Ltd - Financial Result for the Quarter ended 30th Sep'26 (Consolidated, INR Crores) Segmental Performance Diagnostic Testing Services ■ Revenue: 257 (+27.4% YoY | +13.5% QoQ) ■ EBIT: 71.5 (+25.6% YoY | +15.5% QoQ) ■ EBIT Margin (%): 27.9 (-40 bps YoY | +49 bps QoQ) Imaging Services ■ Revenue: 13.6 (-4.6% YoY | +0.5% QoQ) ■ EBIT: 2.1 (+16.1% YoY | +65.9% QoQ) ■ EBIT Margin (%): 15.4 (+275 bps YoY | +608 bps QoQ) Others ■ Revenue: 0.5 (-32.5% YoY | +57.6% QoQ) ■ EBIT: 0.6 (+18.0% YoY | +118.5% QoQ) ■ EBIT Margin (%): 113 (+4853 bps YoY | +3164 bps QoQ)
Thyrocare Technologies Limited cordially invites you to its "Q2 FY2026-27 Earnings Call" to be held on Thursday, October 29, 2026 at 06.00 P.M. to discuss the financial performance of the ....
Intimation · 29 Oct 2026, 6:00 pm
Thyrocare Technologies Schedules Q2 FY27 Earnings Call on 29th Oct'26 Thyrocare Technologies Limited will host an earnings conference call on 29th Oct'26 at 06:00 PM IST to discuss its unaudited financial results for the quarter and half-year ended 30th Sep'26 (Q2 FY27). Senior management, including MD & CEO Rahul Guha, CFO Vikram Gupta, COO Dr. Ramesh Kinha, and CCO Rajdeep Panwar, will represent the company. Dial-in access is available via universal numbers +91 22 6280 1408 and +91 22 7115 8296.
Thyrocare Technologies Limited has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 29 Oct 2026, 5:30 am
Thyrocare Technologies Limited has informed the Exchange about Board Meeting to be held on Thursday, October 29, 2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the quarter and half year ended September 30, 2026
Intimation · 29 Oct 2026, 5:30 am
Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve the Unaudited Standalone ....
Intimation · 29 Oct 2026, 5:30 am
Thyrocare Technologies Schedules Board Meeting for Q2 FY27 Financial Results Thyrocare Technologies Limited announced that its Board of Directors will meet on 29th Oct'26 to consider and approve the unaudited standalone and consolidated financial results for the quarter and half-year ended 30th Sep'26. The company noted that the insider trading window, closed since 1st Oct'26 for designated persons and their immediate relatives, will reopen 48 hours after the declaration of the financial results.
Please find attached herewith Intimation relating Grant of Options under Thyrocare Employee Stock Option Scheme
Others (Uncategorized) · 24 Sept 2026, 10:14 pm
Thyrocare Technologies Grants 1.92 Lakh ESOPs at Rs. 10 Exercise Price Thyrocare Technologies Limited’s Nomination and Remuneration Committee approved the grant of 1,92,000 stock options to eligible employees on 24th Sep'26 under its Employee Stock Option Scheme. Each option is convertible into one equity share of face value Rs. 10 at an exercise price of Rs. 10 per option. The options vest equally at one-third each year over a three-year period, contingent on continuous employment, and carry an exercise period of up to seven years from the respective vesting dates.
Please find attached Intimation Letter
Others (Uncategorized) · 21 Sept 2026, 8:36 pm
Thyrocare Divests Radiology Subsidiary Nueclear Healthcare for Rs 141.40 Crore Thyrocare Technologies approved divesting 100% of its wholly owned subsidiary Nueclear Healthcare Limited (NHL) to Trovera Healthcare for ~Rs 141.40 cr to focus on core pathology. The consideration comprises Rs 81.90 cr in cash (subject to working capital adjustments) and Rs 59.50 cr via 42,500 CCPS of Trovera (~4.5% fully diluted stake). Simultaneously, Thyrocare will acquire NHL's Gurugram and Hyderabad lab properties for Rs 20.59 cr. NHL contributed Rs 44.62 cr (5.38%) to FY26 consolidated revenue. The transaction expects completion by 30th Nov'26, subject to shareholder approval.
Please find attached intimation regarding Acquisition of Compulsorily Convertible Preference Shares of Trovera Healthcare Private Limited as part-consideration for the sale of Nueclear ....
Others (Uncategorized) · 21 Sept 2026, 8:32 pm
Thyrocare Divests Radiology Arm Nueclear Healthcare to Trovera for Rs 141.4 Crore Thyrocare Technologies' board approved divesting 100% of wholly owned subsidiary Nueclear Healthcare Limited to Trovera Healthcare for ~Rs 141.40 cr to focus on core pathology. The consideration comprises Rs 81.90 cr in cash (subject to working capital adjustments) and 42,500 CCPS of Trovera valued at Rs 59.50 cr (~4.5% diluted stake). Simultaneously, Thyrocare will acquire operating lab properties in Gurugram and Hyderabad from NHL for Rs 20.59 cr. The transaction requires shareholder approval and is targeted to close by 30th Nov'26.
Outcome of the Board meeting held on Monday, September 21, 2026
Outcome · 21 Sept 2026, 8:27 pm
Thyrocare Divests Nueclear Healthcare for Rs 141.4 Crore to Focus on Pathology Thyrocare Technologies approved divesting its 100% stake in wholly owned subsidiary Nueclear Healthcare Limited (NHL) to Trovera Healthcare for ~Rs 141.40 crore to exit radiology and focus on core pathology. The consideration comprises Rs 81.90 crore in cash and Rs 59.50 crore via 42,500 CCPS (~4.5% fully diluted stake) of Trovera. NHL contributed Rs 44.62 crore (5.38%) to consolidated turnover and Rs 83.55 crore (14.27%) to net worth in FY26. Additionally, Thyrocare will purchase NHL's Gurugram and Hyderabad lab properties for Rs 20.59 crore.
The Exchange has received revised Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on September 08, 2026 for Docon Technologies ....
Encumbered Shares - Invocation / Release · 09 Sept 2026, 5:52 pm
API Holdings Releases Full Pledge on 49.93% Stake in Thyrocare Technologies Docon Technologies fully released its pledge on 7,94,69,696 equity shares of Thyrocare Technologies, representing 49.93% of total share capital, on 17th Aug'26. This follows API Holdings’ complete redemption and repayment of INR 10,500 mn in outstanding NCDs on 14th Aug'26. Consequently, no encumbrance remains on the promoter holding of 8,12,00,000 shares (51.02%). Additionally, Docon amalgamated into parent API Holdings effective 3rd Sep'26 post-NCLT approval, vesting all assets and liabilities into API Holdings as the successor entity.
The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for API Holdings Ltd
Others (Uncategorized) · 04 Sept 2026, 10:00 pm
API Holdings Directly Absorbs 51.02% Stake in Thyrocare Following Docon Amalgamation API Holdings has completed its amalgamation with Docon Technologies following NCLT Mumbai approval on 31st Aug'26 and RoC filing on 3rd Sep'26. Effective 3rd Sep'26, Docon stands merged into API Holdings, resulting in the direct transmission and vesting of Docon's entire holding of 8,12,00,000 equity shares (51.02% stake) in Thyrocare Technologies to API Holdings. The transaction was executed under SEBI Takeover Regulation 10(1)(d)(iii) exemptions, leaving the overall promoter and promoter group aggregate shareholding in Thyrocare unchanged.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for API Holdings Ltd
Acquisition/ Disposal of Shares · 04 Sept 2026, 8:29 pm
API Holdings Directly Vests 51.02% Stake in Thyrocare Post-Amalgamation API Holdings has directly acquired an 8,12,00,000 equity shareholding (51.02% of paid-up capital, 50.87% diluted) in Thyrocare Technologies following the NCLT-sanctioned merger of Docon Technologies into API Holdings. The scheme became effective on 3rd Sep'26 upon filing with the RoC, following NCLT approval on 31st Aug'26. As Docon stands amalgamated, its entire Thyrocare stake transferred to API Holdings by operation of law, resulting in no change in the overall promoter group aggregate shareholding.
Please find enclosed the Intimation regarding approval of Scheme of Amalgamation of Docon Technologies Private Limited with API Holdings Limited
Others (Uncategorized) · 01 Sept 2026, 10:51 pm
NCLT Approves Docon-API Holdings Amalgamation; Thyrocare Promoter Holding Unchanged The National Company Law Tribunal (NCLT) on 31st Aug'26 sanctioned the amalgamation of Docon Technologies with its parent, API Holdings. Consequently, Docon's entire 51.02% stake (81.2M shares) in Thyrocare will be transferred to API Holdings. This internal restructuring within the promoter group results in no change to the aggregate promoter shareholding of 51.02% in Thyrocare. The transaction consolidates the holding under API Holdings, while public shareholding remains unaffected at 48.98%.
Please find enclosed the Intimation regarding complete discharge and release of Transaction Documents pursuant to full redemption and repayment of Non-Convertible Debentures by API Holdings Limited
Others (Uncategorized) · 20 Aug 2026, 2:35 am
Thyrocare: Holding Company API Holdings Discharges Pledge on 60.92% Stake Thyrocare announced the complete release of a share pledge on 19 Aug'26. The pledge, representing 60.92% of the company's equity capital, was held by Docon Technologies on behalf of ultimate holding company API Holdings. This follows the full redemption and repayment of INR 1,700 crore in Non-Convertible Debentures (NCDs) originally issued by API. Catalyst Trusteeship Limited has issued a No-Dues certificate, discharging all transaction documents and freeing up the significant promoter-held stake, which was initially pledged on 15 Sep'25.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd
Acquisition/ Disposal of Shares · 19 Aug 2026, 4:30 pm
Thyrocare: Docon Technologies' Pledge on 49.93% Stake Released Catalyst Trusteeship, acting for API Holdings' debenture holders, disclosed the full release of a pledge on 7.95 crore shares of Thyrocare Technologies on 17 Aug '26. The shares, representing 49.93% of total share capital (49.78% diluted), were pledged by Docon Technologies Private Limited. The release follows the full repayment and redemption of Non-Convertible Debentures. Post-release, the acquirer group's encumbered holding in Thyrocare is nil. Docon is a promoter entity of Thyrocare.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Docon Technologies Pvt Ltd & PACs
Acquisition/ Disposal of Shares · 18 Aug 2026, 4:48 pm
Thyrocare Promoter Docon Technologies Releases Pledge on 10.99% Stake Promoter Docon Technologies has released a pledge on 1.75 crore equity shares of Thyrocare Technologies, equivalent to a 10.99% stake, on 11 Aug'26. This action was taken in connection with Non-Convertible Debentures issued by API Holdings, Docon's parent. Post-release, the promoter's total encumbered shareholding reduced from 60.92% (9.70 crore shares) to 49.93% (7.95 crore shares). Docon’s overall shareholding in Thyrocare remains unchanged at 60.92%, with the promoter continuing to hold voting rights on all its shares.
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Docon Technologies Pvt Ltd
Acquisition/ Disposal of Shares · 18 Aug 2026, 4:45 pm
Thyrocare: Promoter Docon Tech Releases Entire Pledged Shareholding Promoter Docon Technologies has released its entire pledged holding of 7.95 crore shares (49.93% stake) in Thyrocare on Aug 17, '26. The release follows full repayment of INR 10,500 million in Non-Convertible Debentures (NCDs) by API Holdings, Docon's ultimate holding company, on Aug 14, '26. After this event, the promoter's entire 51.02% stake in Thyrocare is free from any encumbrance. Docon's total shareholding remains unchanged at 8.12 crore shares. The NCD repayment was partly funded by internal accruals at API.
The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for HSBC Mutual Fund
Acquisition/ Disposal of Shares · 18 Aug 2026, 4:28 pm
HSBC Mutual Fund Increases Stake in Thyrocare Technologies Above 5% HSBC Mutual Fund increased its shareholding in Thyrocare Technologies Limited, crossing the 5% threshold. On 13-Aug-26, the fund acquired 29,99,731 shares, representing 1.88% of the company's capital, via an open market purchase. This transaction increased its total holding from 75,57,935 shares (4.75%) to 1,05,57,666 shares (6.63%). The disclosure, dated 17-Aug-26, was made under SEBI's substantial acquisition regulations.